Ibandronate Sodium 150MG Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-21-D-0128

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
This procurement notice announces the award of a Firm Fixed Price Requirements Contract for the supply of Ibandronate Sodium 150MG Tablets, packaged in sets of three. The contract is managed by DLA Troop Support, a federal office responsible for ensuring the timely and efficient provision of pharmaceutical products to meet government needs. The procurement falls under NAICS Code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating its focus on drugs and biologicals. The primary objective of this contract is to secure a reliable source of Ibandronate Sodium 150MG tablets, a medication commonly used in the treatment of osteoporosis and related conditions. The contract is structured as a requirements contract, meaning the government will order quantities as needed over the contract period, with pricing fixed at the time of award. This approach ensures both cost predictability and supply flexibility to meet fluctuating demand. The procurement was conducted under full and open competition, inviting all qualified manufacturers and suppliers within the pharmaceutical sector to participate. This competitive process is designed to ensure the government receives the best value in terms of quality, price, and delivery capability. There are no set-aside requirements indicated, suggesting that the opportunity was not restricted to small businesses or other socioeconomic categories. Key deliverables under this contract include the consistent and timely delivery of Ibandronate Sodium 150MG tablets in the specified packaging configuration. Contractors are expected to adhere to all applicable regulatory standards for pharmaceutical manufacturing and supply, ensuring product safety, efficacy, and compliance with federal requirements. The contracting activity is overseen by Kevin Rafferty, who serves as the primary point of contact for all matters related to this award. Interested parties or current contractors may reach Mr. Rafferty via email at [email protected] or by phone at 215-737-0907 for further information or clarification. This award notice remains active as of the posting date, February 4, 2024. Additional details, including attachments relevant to the contract, can be accessed through the official SAM.gov opportunity listing at https://sam.gov/opp/4188d38e2d0f432b9eb68a0eace2d378/view. Overall, this contract represents a significant opportunity for pharmaceutical manufacturers with the capability to supply high-quality Ibandronate Sodium 150MG tablets in compliance with federal standards and requirements. The long-term, requirements-based nature of the contract offers the potential for ongoing business with the federal government, contingent upon consistent performance and adherence to contract terms.
Documents7